Relationship among α-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 8, 2006, Pages 808-815

  Mori, Fumiaki ^a,d   Nishie, Makoto ^a   Kakita, Akiyoshi ^b   Yoshimoto, Makoto ^c   Takahashi, Hitoshi ^b   Wakabayashi, Koichi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c Medicinal Research Laboratories   (Japan)

^d INST D INVESTIGACIONS B   (Spain)

Author keywords

Synuclein; Neuromelanin; Neuronal cell death; Parkinson disease; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ARTICLE; AUTOPSY; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINE RELEASE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LOCUS CERULEUS; NERVE DEGENERATION; PARKINSON DISEASE; PIGMENTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CELL DEATH; CELL SURVIVAL; CYTOPROTECTION; DOPAMINE; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; LOCUS COERULEUS; MIDDLE AGED; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 33746893477     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000230520.47768.1a     Document Type: Article

References (42)

1. Bogerts B. A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. J Comp Neurol 1981;197:63-80
2. Saper CB, Petito CK. Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups. Brain 1982;105:87-101
3. Sulzer D, Bogulavsky J, Larsen KE, et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 2000;97:11869-74
4. Zecca L, Fariello R, Riederer P, et al. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 2002;510:216-20
5. Gaspar P, Berger B, Gay M, et al. Tyrosine hydroxylase and methionine-enkephalinin the human mesencephalon. Immunocytochemical localization and relationships. J Neurol Sci 1983;58:247-67
6. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-48
7. Spillantini MG, Schmidt ML, Lee VM, et al. α-Synuclein in Lewy bodies. Nature 1997;388:839-40
8. Baba M, Nakajo S, Tu P-H, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-84
9. Takeda A, Mallory M, Sundsmo M, et al. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am J Pathol 1998;152:367-72
10. Wakabayashi K, Hayashi S, Kakita A, et al. Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 1998;96:445-52
11. Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated α-synuclein in aging human brain. J Neuropathol Exp Neurol 2003;62:644-54
12. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: Dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003;62:1241-53
13. Fujiwara H, Hasegawa M, Dohmae N, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-64
14. Perez RG, Waymire JC, Lin E, et al. A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002;22:3090-99
15. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
16. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
17. Piao YS, Mori F, Hayashi S, et al. α-Synuclein pathology affecting Bergmannglia of the cerebellum in patients with α-synucleinopathies. Acta Neuropathol 2003;105:403-409
18. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-96
19. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991;114:2283-301
20. den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems inidiopathic paralysis agitans. J Neurol Neurosurg Paychiatry 1960;23:283-90
21. Tomonaga M. Neuropathology of the locus ceruleus: A semi-quantitative study. J Neurol 1983;230:231-40
22. Gibb WR, Scott T, Lees AJ. Neuronal inclusions of Parkinson's disease. Mov Disord 1991;6:2-11
23. Tompkins MM, Hill WD. Contribution of somal Lewy bodies to neuronal death. Brain Res 1997;775:24-49
24. Del Tredici K, Rub U, deVos RA, et al. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-26
25. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
26. Gibb WR, Narabayashi H, Yokochi M, et al. New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology 1991;41:820-22
27. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: Clinical and pathologic study in a family. Neurology 1994;44:437-41
28. Oyanagi K, Takeda S, Takahashi H, et al. A quantitative investigation of the substantia nigra in Huntington's disease. Ann Neurol 1989;26:13-19
29. Kihira T, Yoshida S, Yoshimasu F, et al. Involvement of Onuf's nucleus in amyotrophic lateral sclerosis. J Neurol Sci 1997;147:81-88
30. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 2000;287:1265-69
31. Matsuoka Y, Vila M, Lincoln S, et al. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001;8:535-39
32. Auluck PK, Chan HY, Trojanowski JQ, et al. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002;295:865-68
33. Giasson BI, Duda JE, Quinn SM, et al. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002;34:521-33
34. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, et al. Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp Neurol 2002;175:35-48
35. Gomez-Isla T, Irizarry MC, Mariash A, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice. Neurobiol Aging 2003;24:245-58
36. Hasegawa T, Matsuzaki M, Takeda A, et al. Accelerated α-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res 2004;1013:51-59
37. Hashimoto M, Rockenstein E, Masliah E. Transgenic models of α-synuclein pathology past, present, and future. Ann N Y Acad Sci 2003;991:171-88
38. Cappai R, Leck SL, Tew DJ, et al. Dopamine promotes α-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEBJ 2005;19:1377-79
39. Lotharius J, Brundin P. Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 2002;11:2395-407
40. Perez RG, Hastings TG. Could a loss of α-synuclein function put dopaminergic neurons at risk? J Neurochem 2004;89:1318-24
41. Xu J, Kao SY, Lee FJ, et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600-6
42. Sidhu A, Wersinger C, Vernier P. Does α-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEBJ 2004;18:637-47